Emile Voest
28-09-2021
More and more cancer drugs are only suitable for a small group of patients. However, we are often not capable to find these patients. That is why every patient with metastatic cancer should be genetically screened before starting treatment.
Back to newsMore news
New study using Hartwig Medical Foundation data maps how breast cancer’s genetic makeup shifts when it spreads
16-07-2026
Analysis of nearly 1,300 tumor genomes across ten genomic subtypes points to candidate drug targets and biomarkers for metastatic breast …
GLOW: working toward more treatment options for glioblastoma
23-05-2023
The outlook for patients with glioblastoma has been unfavorable for years, and treatment options remain limited. That is a reason …
The value of the GENAYA project for patients of the future
09-04-2026
The GENAYA project has been extended through 2028. A total of 39 hospitals now participate in the project, which is led by …
Hartwig’s unique data set has enriched our understanding of metastatic cancer.
Bioinformatician - PhD student at Erasmus University Medical Center